- Bachelor of Pharmacy, Amity University, India (2019)
- Molecular biology
- Role of genetics in disease development
- Action mechanisms of neuropharmacological drugs and pathophysiology of neurological diseases such as Alzheimer's and Parkinson's
Former Lab Members
Our research is directed toward an understanding of the mechanisms involved in neuropsychiatric and neurodegenerative disorders. Currently, we are examining novel post-translation modifications and signaling pathways for serotonin receptors. Serotonin receptor signaling is targeted by a number of drugs used to treat mood disorders such as depression and anxiety and psychiatric disorders including schizophrenia. For example, we recently found that serotonin 1A receptors are SUMOylated and that the SUMOylated receptor is not able to bind to serotonin ligands. We also found a novel estrogen receptor system GPER1 modifies serotonin receptor signaling and is a potential target for the treatment of depression and other mood disorders associated with the onset of menopause.
Research is also directed toward finding new targets for drug development for neurodegenerative diseases. For example, we were recently funded to identify biological probes that disrupt the abnormal interaction of mutant huntingtin protein. The long-term goal is to produce biological probes for possible future drug development to prevent the progressive neurodegeneration in Huntington’s disease.
- Postdoctoral Fellowship, Johns Hopkins University School of Medicine, Baltimore, MD (1989)
- Ph.D., Pharmacology, University of Louisville, Louisville, KY (1985)
- Professor, Chair, Department of Pharmacology & Toxicology, University of Kansas, Lawrence KS
- Professor, Department of Pharmacology, Loyola University Chicago School of Medicine
- Assistant Professor, Johns Hopkins School of Medicine
Nancy Muma has a long-standing interest in neuropharmacology. Her research is currently focused on the development of biological probes and drug discovery for Huntington’s disease as well as investigations into novel serotonin signaling pathways and their impact in serotonin-related disorders including depression and schizophrenia.